雷替曲塞在晚期结直肠癌中的应用研究进展  

The progression of exploratory development of raltitrexed in colorectal cancer

作　　者：应怀昌[1] 叶舟[2] 

机构地区：[1]中国人民解放军73301部队医院 [2]南京军区福州总医院

出　　处：《现代肿瘤医学》2012年第6期1318-1320,共3页Journal of Modern Oncology

摘　　要：胸苷合成酶(thymidylate synthase,TS)催化脱氧尿苷通过甲基化转变成脱氧尿嘧啶单磷酸核苷(deoxythymidine monophosphate,dTMP),是细胞合成dTMP的限速酶。因此,TS成为生化研究及抗肿瘤药物开发的重要靶点。近10年来,许多学者致力于研究各种新型胸苷酸合酶抑制剂在晚期结直肠癌治疗中的作用机制及治疗效果。雷替曲塞做为新一代水溶性胸苷酸合酶抑制剂,通过特殊的转运与代谢方式达到良好的抗肿瘤作用,并取得显著的优势。本文就雷替曲塞在晚期结直肠癌治疗中的进展状况进行分析和讨论。Thymidine synthase（thymidylate synthase,TS） catalysises the methylation of deoxyuridine into deoxyuridine monophosphate（deoxythymidine monophosphate,dTMP）.It is the limiting enzyme of the synthesis of dTMP in cells.So it becomes an important target of biochemical research and anti-tumor drug development.Over the past 10 years,many researchers have been working on the mechanism and the efficiency of a variety of new thymidylate synthase inhibitors in the treatment of advanced colorectal cancer.Raltitrexed is a new generation of water-soluble thymidylate synthase inhibitor.It can be intaken by the specific transport and metabolism,then can achieve good anti-tumor effect and significant advantage.In this paper,the progression of exploratory development of raltitrexed is analyzed and discussed.

关 键 词：雷替曲塞 胸苷合成酶抑制剂 结直肠癌 

分 类 号：R735.35[医药卫生—肿瘤] R735.37[医药卫生—临床医学]